Abstract
The tyrosine kinase epidermal growth factor receptor (EGFR) has emerged in recent years as a key and validated target of targeted therapies for solid tumors. It plays a central role in oncology since it is involved in many steps of tumor progression such as proliferation, angiogenesis, invasiveness, decreased apoptosis, and loss of differentiation. Recent advances in targeted therapies have demonstrated that tyrosine kinase inhibitors (TKIs), have provided a marked benefit to subsets of patients whose tumors harbor specific genetic abnormalities. However, resistance phenomenon appears rapidly and patients with EGFR mutations acquire resistance to TKI inhibitors decreasing therefore the median time to disease progression to few months. Several strategies were envisioned to overcome this resistance, such as dual–target inhibitors, multitarget and combined therapy. This review summarizes recent advances in TKIs development with special focus on rational strategies for the design of potent EGFR inhibitors including molecular modeling studies based on crystallographic data. Such advances open the way for new research possibilities in modern medicinal chemistry combined to structure-based drug design.
Keywords: Breast cancer, drug design, EGFR, irreversible inhibitors, NSCLC, mutation, reversible inhibitors
Current Medicinal Chemistry
Title:Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Volume: 20 Issue: 16
Author(s): P. Warnault, A. Yasri, M. Coisy-Quivy, G. Cheve, C. Bories, B. Fauvel and R. Benhida
Affiliation:
Keywords: Breast cancer, drug design, EGFR, irreversible inhibitors, NSCLC, mutation, reversible inhibitors
Abstract: The tyrosine kinase epidermal growth factor receptor (EGFR) has emerged in recent years as a key and validated target of targeted therapies for solid tumors. It plays a central role in oncology since it is involved in many steps of tumor progression such as proliferation, angiogenesis, invasiveness, decreased apoptosis, and loss of differentiation. Recent advances in targeted therapies have demonstrated that tyrosine kinase inhibitors (TKIs), have provided a marked benefit to subsets of patients whose tumors harbor specific genetic abnormalities. However, resistance phenomenon appears rapidly and patients with EGFR mutations acquire resistance to TKI inhibitors decreasing therefore the median time to disease progression to few months. Several strategies were envisioned to overcome this resistance, such as dual–target inhibitors, multitarget and combined therapy. This review summarizes recent advances in TKIs development with special focus on rational strategies for the design of potent EGFR inhibitors including molecular modeling studies based on crystallographic data. Such advances open the way for new research possibilities in modern medicinal chemistry combined to structure-based drug design.
Export Options
About this article
Cite this article as:
Warnault P., Yasri A., Coisy-Quivy M., Cheve G., Bories C., Fauvel B. and Benhida R., Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors, Current Medicinal Chemistry 2013; 20 (16) . https://dx.doi.org/10.2174/0929867311320160001
DOI https://dx.doi.org/10.2174/0929867311320160001 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unveiling Cancer in IBD: Screening Colonoscopy or Chromoendoscopy
Current Drug Targets P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews Hepatocarcinogenesis and Ceramide/Cholesterol Metabolism
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450-Mediated Estrogen Metabolites and Autoimmunity: Relationship and Link to Free Radicals
Current Drug Metabolism Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery Choice of Treatment with Antidepressants: Influencing Factors
Current Pharmaceutical Design Enhancing Oral Bioavailability of Methylnaltrexone Using an Emulsion Formulation
Letters in Drug Design & Discovery Pharmacogenetics in Laboratory Diagnostics
Current Pharmacogenomics and Personalized Medicine Cancer Stem Cells and Therapeutic Perspectives
Current Medicinal Chemistry Isolation of Secreted microRNAs (miRNAs) from Cell-conditioned Media
MicroRNA New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Overview of Current Practice and Future Trends in Thromboprophylaxis for General Surgery
Vascular Disease Prevention (Discontinued) Developmental Expression of the Translocator Protein 18 kDa (TSPO) in Testicular Germ Cells
Current Molecular Medicine Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives
Mini-Reviews in Medicinal Chemistry Diverse Thiophenes as Scaffolds in Anti-cancer Drug Development: A Concise Review
Mini-Reviews in Medicinal Chemistry Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry In Vitro Blood-Brain Barrier Models – Latest Advances and Therapeutic Applications in a Chronological Perspective
Mini-Reviews in Medicinal Chemistry